Multiple sclerosis (MS) sufferers in Scotland are to be the first in the UK to get a new drug that can improve their quality of life on the NHS.
The Scottish Medicines Consortium (SMC) has accepted Pledigry as a treatment for adults with the most common form of MS.
Some 85% of MS patients have the relapsing remitting form of the disease, where they have distinct attacks of symptoms which then fade away either partially or completely.
The new treatment was accepted by the SMC after MS groups argued Pledigry can offer patients a better quality of life as it requires them to have fewer injections each week than the other treatments that are available.
Mark O'Donnell, director at the MS Society Scotland, said: "Today's decision by the SMC is positive news for people living in Scotland with relapsing remitting MS, who will now be the first in the UK to have routine access to this drug through the NHS.
"It supports our fight, through our Treat Me Right campaign, for improved access to MS medicines for people across Scotland.
"The SMC's approval of Plegridy also represents a further step forward in the treatment of MS and improves the overall range of choice for people living with MS.
"This drug is designed to stay in the body longer so it requires less frequent injections, which people with MS have told us reduces the discomfort and disruption to their lives.
"Given its potential to improve a person's quality of life we look forward to seeing Plegridy made available to all Scots who could benefit from it."
The drug was one of six medicines that the SMC approved for use in the NHS in Scotland, including cetuximab, which was approved as a first-line treatment for bowel cancer patients where the disease has spread to other parts of the body.
It was approved as part of new processes adopted by the SMC which aim to improve access to medicines for those at the end of life and with rare conditions.
Professor Jonathan Fox, chairman of the SMC, said: "I am pleased that this month SMC has accepted six medicines for a variety of conditions that will benefit patients in Scotland.
"Two of these medicines were considered through our PACE process, and patient groups and clinicians gave powerful testimony on the benefits of cetuximab for bowel cancer and aztreonam lysine in cystic fibrosis."
Prof Fox said the SMC was "disappointed" not to have been able to approve bevacizumab (also known as Avastin) for the treatment of ovarian cancer.
He added: "Despite applying as much flexibility as we could, the committee was not satisfied it would be a cost-effective use of NHS resources."
Why are you making commenting on The Herald only available to subscribers?
It should have been a safe space for informed debate, somewhere for readers to discuss issues around the biggest stories of the day, but all too often the below the line comments on most websites have become bogged down by off-topic discussions and abuse.
heraldscotland.com is tackling this problem by allowing only subscribers to comment.
We are doing this to improve the experience for our loyal readers and we believe it will reduce the ability of trolls and troublemakers, who occasionally find their way onto our site, to abuse our journalists and readers. We also hope it will help the comments section fulfil its promise as a part of Scotland's conversation with itself.
We are lucky at The Herald. We are read by an informed, educated readership who can add their knowledge and insights to our stories.
That is invaluable.
We are making the subscriber-only change to support our valued readers, who tell us they don't want the site cluttered up with irrelevant comments, untruths and abuse.
In the past, the journalist’s job was to collect and distribute information to the audience. Technology means that readers can shape a discussion. We look forward to hearing from you on heraldscotland.com
Comments & Moderation
Readers’ comments: You are personally liable for the content of any comments you upload to this website, so please act responsibly. We do not pre-moderate or monitor readers’ comments appearing on our websites, but we do post-moderate in response to complaints we receive or otherwise when a potential problem comes to our attention. You can make a complaint by using the ‘report this post’ link . We may then apply our discretion under the user terms to amend or delete comments.
Post moderation is undertaken full-time 9am-6pm on weekdays, and on a part-time basis outwith those hours.
Read the rules hereComments are closed on this article